

Evelo Biosciences to Host Quarterly Corporate Update Conference Call on Thursday, May 2, 2019

April 25, 2019

CAMBRIDGE, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO) ("Evelo"), a clinical stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines, today announced that it will host a conference call and live webcast at 8:30 A.M. ET on Thursday, May 2, 2019 to report its first quarter financial results and discuss recent business updates.

To access the live conference call, please dial 1-866-795-3242 (domestic) or 1-409-937-8909 (international) and refer to conference ID 1838168. A live webcast of the event will also be available under "News and Events" in the Investors section of Evelo's website at <http://ir.evelobio.com>. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.

About Evelo Biosciences

Evelo Biosciences, Inc. is a clinical-stage biotechnology company developing monoclonal microbials, a potential new modality of oral biologic medicines. Evelo's product candidates are single strains of microbes, selected for defined pharmacological properties. They are developed to activate multiple naturally evolved biological pathways by engaging immune cells that link the small intestine to the rest of the body. Evelo believes that monoclonal microbials have the potential to be broadly applicable across many immune-mediated diseases including inflammation, cancer and autoimmune diseases.

Evelo currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer, for which ten clinical readouts are expected during 2019 and 2020. Evelo is also advancing additional candidates through preclinical development in other disease areas.

For more information, please visit www.evelobio.com.

Contact

Evelo Biosciences
Stefan Riley
617-577-0300
stefan@evelobio.com



Source: Evelo Biosciences, Inc.